solut
deterg
like
tween
polysorb
triton
octoxynol
nachol
addit
requir
begin
develop
combin
ether
tween
use
due
explos
natur
sd
mixtur
replac
tnbp
nachol
combin
still
use
base
improv
sd
technolog
tnbp
tween
commonli
use
combin
today
meanwhil
effect
combin
demonstr
includ
tnbptriton
tnbp
mixtur
differ
deterg
success
inactiv
human
pathogen
virus
human
immunodefici
viru
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
model
virus
sindbi
viru
sinv
sendai
viru
bovin
viral
diarrhea
viru
bvdv
vesicular
stomat
viru
vsv
report
new
york
blood
center
today
manufactur
plasma
deriv
must
investig
relev
process
step
welldefin
laboratori
scale
demonstr
viral
safeti
product
viru
valid
studi
must
follow
intern
guidelin
recommend
addit
valid
product
condit
guidelin
requir
demonstr
robust
viru
inactiv
method
investig
limit
product
condit
condit
even
beyond
limit
consequ
manufactur
plasmaderiv
medicin
product
worldwid
investig
similar
condit
sd
treatment
use
nearli
ident
spectra
test
virus
gener
nearli
ident
set
data
thu
signific
amount
inform
viru
inactiv
sd
treatment
avail
meanwhil
part
remain
unpublish
conceal
archiv
compani
regulatori
author
make
data
avail
regulatori
author
physician
patient
organ
research
support
care
virussaf
plasma
deriv
develop
countri
also
reinforc
efficaci
robust
sd
technolog
seven
plasma
protein
therapeut
associ
ppta
member
compani
consolid
data
viru
inactiv
factor
f
viii
f
ix
intraven
immun
globulin
ivig
intramuscular
immunoglobulin
imig
result
total
studi
present
includ
valid
product
robust
condit
data
sd
treatment
gener
seven
ppta
member
compani
collect
made
anonym
data
collect
compris
process
differ
manufactur
includ
differ
product
differ
combin
solvent
deterg
differ
product
variabl
temperatur
protein
concentr
ph
incub
time
concentr
virusinactiv
agent
data
viru
inactiv
product
condit
n
data
robust
studi
n
includ
total
data
studi
collect
evalu
fviii
n
f
ix
n
ivig
n
imig
n
differ
sd
procedur
compris
combin
tnbp
tween
n
triton
n
triton
plu
tween
n
nachol
n
data
viru
viru
valid
studi
provid
appendix
avail
support
inform
onlin
version
paper
tabl
relev
process
variabl
sd
treatment
summar
compar
variabl
product
scale
investig
robust
studi
robust
studi
process
variabl
investig
either
upper
andor
lower
limit
product
rang
even
significantli
beyond
limit
tabl
concentr
solvent
deterg
list
except
one
sd
procedur
gl
tnbp
use
product
scale
broader
rang
lower
concentr
solvent
deterg
investig
robust
studi
virus
use
studi
tabl
chosen
complianc
current
intern
guidelin
viru
valid
note
neither
hcv
hbv
propag
cell
cultur
therefor
appropri
model
virus
use
instead
virus
obtain
differ
sourc
eg
american
type
cultur
collect
propag
suscept
cell
line
determin
kinet
viru
inactiv
sampl
taken
immedi
dilut
termin
sd
treatment
subsequ
dilut
screen
infect
assay
viru
titer
calcul
accord
spearman
kaerber
viru
inactiv
capac
express
log
viru
reduct
factor
lrf
calcul
compar
viru
titer
defin
time
point
exposur
sd
complianc
current
intern
guidelin
viru
valid
whenev
residu
infect
detect
correspond
viru
reduct
factor
report
greater
equal
viru
reduct
factor
order
log
higher
usual
reflect
viru
inactiv
capac
significantli
contribut
overal
safeti
finish
product
howev
actual
lrf
strongli
depend
dynam
rang
assay
mainli
limit
follow
factor
titer
volum
viru
spike
sampl
dilut
necessari
avoid
cytotox
due
tnbp
deterg
sampl
volum
plate
onto
cell
cultur
viru
detect
data
present
deriv
studi
cover
timedepend
inactiv
test
viru
inactiv
kinet
studi
shown
data
first
time
point
summar
viru
inactiv
limit
detect
highest
viru
reduct
factor
achiev
eg
lrf
valu
min
fig
robust
studi
residu
infect
found
extrem
condit
viru
reduct
factor
obtain
end
incub
time
given
lrf
repres
entir
valid
studi
kinet
viru
inactiv
sd
treatment
inactiv
data
differ
time
point
present
figur
mean
valu
rang
highest
lowest
valu
shown
vertic
bar
whenev
necessari
data
tightli
neighbor
time
point
concentr
accumul
data
incub
time
minut
minut
combin
inactiv
data
tnbp
concentr
less
less
gl
accumul
accumul
data
also
use
temperatur
protein
concentr
ph
valu
viru
inactiv
data
studi
summar
fig
irrespect
combin
solvent
deterg
product
process
variabl
concentr
solvent
deterg
protein
concentr
temperatur
ph
lrf
valu
plot
versu
incub
time
includ
studi
perform
product
condit
robust
studi
investig
paramet
significantli
deviat
product
condit
figur
show
rang
inactiv
mean
valu
time
point
number
studi
involv
rang
virus
use
list
tabl
studi
product
condit
defin
studi
concentr
sd
insignificantli
chang
fig
data
obtain
product
condit
summar
compris
virus
differ
class
product
differ
combin
solvent
deterg
total
studi
evalu
n
studi
pseudorabi
viru
prv
n
bvdv
n
sinv
n
wnv
n
vsv
n
vaccinia
viru
vacv
n
process
variabl
test
rang
ph
valu
protein
concentr
gl
tnbp
concentr
gl
concentr
deterg
rang
studi
perform
product
condit
evalu
potenti
influenc
differ
product
composit
exampl
protein
concentr
ph
buffer
solut
forth
viru
inactiv
fviii
n
f
ix
n
ivig
n
imig
n
viru
inactiv
achiev
log
ivig
log
imig
log
f
ix
log
fviii
four
combin
tnbp
deterg
evalu
tnbp
tween
n
tnbp
triton
n
tnbp
triton
plu
tween
n
tnbp
nachol
n
combin
tnbp
tween
lrf
valu
log
tnbptriton
log
tnbp
triton
plu
tween
log
log
tnbpnachol
mean
valu
rang
inactiv
differ
product
differ
combin
tnbp
deterg
shown
fig
inactiv
log
achiev
hiv
prv
bvdv
equin
arthriti
viru
eav
sinv
vsv
wnv
vacv
test
variabl
describ
studi
product
condit
data
studi
indic
viru
inactiv
significantli
affect
ph
incub
temperatur
protein
concentr
product
condit
two
differ
concentr
tnbp
appli
gl
except
three
studi
perform
gl
studi
perform
gl
deterg
concentr
vari
gl
nachol
gl
tween
gl
triton
gl
triton
plu
gl
tween
tabl
combin
solvent
deterg
viru
inactiv
factor
rang
log
two
concentr
tnbp
gl
combin
differ
deterg
show
influenc
viru
inactiv
total
studi
process
robust
perform
condit
concentr
tnbp
deterg
significantli
deviat
product
condit
studi
evalu
differ
protein
concentr
incub
temperatur
ph
valu
product
combin
solvent
deterg
reduc
incub
time
tabl
concentr
tnbp
rang
gl
potenti
influenc
differ
product
viru
inactiv
investig
fiftyseven
studi
perform
fviii
studi
f
ix
studi
ivig
studi
imig
studi
tnbp
concentr
lower
concentr
use
product
condit
despit
major
deviat
standard
concentr
viru
inactiv
log
achiev
lrf
valu
log
consid
nonsignific
inactiv
found
drastic
reduc
sd
concentr
studi
discuss
separ
figur
four
combin
tnbp
deterg
investig
tnbp
tween
n
tnbp
triton
plu
tween
n
tnbp
concentr
viru
inactiv
observ
fig
total
studi
robust
evalu
potenti
influenc
ph
viru
inactiv
robust
studi
irrespect
process
variabl
perform
rang
ph
ph
viru
inactiv
achiev
log
variat
ph
valu
result
reduc
viral
inactiv
capac
fig
observ
protein
concentr
viru
reduct
valu
log
nonsignific
found
drastic
reduc
sd
concentr
total
robust
studi
conduct
evalu
influenc
incub
temperatur
viru
inactiv
major
robust
studi
n
perform
result
lrf
valu
log
thirtyfour
studi
cover
rang
lrf
valu
log
nine
studi
perform
incub
temperatur
lrf
valu
log
influenc
incub
temperatur
viru
inactiv
found
rang
test
fig
lrf
valu
log
nonsignific
found
drastic
reduc
sd
concentr
total
studi
perform
significantli
reduc
concentr
tnbpdeterg
less
concentr
product
scale
correspond
gl
instead
gl
studi
perform
ivig
imig
n
fviii
n
f
ix
n
viru
inactiv
data
shown
fig
plot
versu
concentr
tnbp
variabl
incub
temperatur
protein
concentr
gl
ph
valu
ph
incub
time
min
taken
consider
twentynin
studi
even
perform
tnbp
concentr
less
standard
concentr
major
studi
n
inactiv
viru
limit
detect
andor
inactiv
log
demonstr
fig
nine
studi
viru
inactiv
less
log
residu
infect
found
studi
perform
elev
tween
concentr
gl
influenc
elev
deterg
concentr
viru
inactiv
observ
consolid
result
viru
inactiv
sd
treatment
present
seven
ppta
member
compani
demonstr
efficaci
robust
sd
technolog
appli
manufactur
mani
medicin
product
deriv
human
plasma
two
decad
data
collect
four
product
fviii
f
ix
ivig
imig
product
commonli
manufactur
compani
repres
licens
product
although
investig
product
tremend
differ
biochem
composit
properti
potenti
influenc
viru
inactiv
observ
fig
product
condit
mean
valu
viru
inactiv
narrow
rang
log
data
studi
robust
condit
plot
versu
tnbp
concentr
fig
viru
inactiv
less
log
observ
ivig
significantli
reduc
concentr
sd
studi
might
explain
higher
number
studi
perform
ivig
low
concentr
sd
compar
smaller
number
data
avail
fviii
f
ix
condit
concentr
tnbp
higher
nomin
concentr
potenti
influenc
differ
product
mean
valu
viru
inactiv
identifi
regardless
product
combin
tnbp
nachol
tween
triton
triton
plu
tween
test
virus
effect
inactiv
broad
rang
condit
potenti
influenc
differ
combin
solvent
deterg
found
product
condit
fig
fig
robust
studi
viru
inactiv
differ
combin
sd
plot
versu
incub
time
late
time
point
might
indic
slower
kinet
viru
inactiv
howev
data
compris
first
time
point
viru
inactiv
limit
detect
allow
conclus
kinet
inactiv
effici
differ
combin
solvent
deterg
fig
viru
inactiv
capac
plot
versu
tnbp
concentr
low
lrf
valu
log
observ
low
concentr
tnbp
combin
tween
reason
find
might
studi
low
concentr
tnbp
done
combin
tnpbtween
thu
potenti
influenc
might
feign
smaller
number
data
combin
sd
potenti
influenc
differ
combin
mean
valu
viru
inactiv
identifi
also
data
plot
versu
incub
time
mean
valu
inactiv
scatter
around
magnitud
log
inactiv
higher
howev
short
incub
time
robust
studi
result
larger
rang
inactiv
valu
influenc
ph
viru
inactiv
observ
rang
ph
ph
fig
data
indic
ph
percept
influenc
efficaci
sd
treatment
investig
beyond
rang
useless
plasma
deriv
eg
clot
factor
sensit
extrem
ph
valu
addit
obviou
influenc
protein
concentr
fig
viru
inactiv
efficaci
rang
gl
incub
temperatur
investig
case
low
temperatur
test
obviou
influenc
inactiv
test
virus
observ
even
fig
howev
seitz
et
al
describ
significantli
delay
viru
inactiv
compar
combin
tnbp
tallow
deriv
vegetablederiv
tween
studi
present
incub
temperatur
lower
perform
combin
tnbp
triton
ivig
thu
efficaci
low
temperatur
shown
fig
might
specif
product
tnbptriton
combin
figur
demonstr
mean
valu
inactiv
rang
log
thu
potenti
influenc
ph
protein
concentr
temperatur
given
rang
viru
inactiv
identifi
product
scale
sd
treatment
perform
least
minut
product
consider
longer
usual
hr
viru
valid
studi
incub
period
usual
shorter
product
scale
inactiv
virus
limit
detect
achiev
alreadi
minut
exposur
sd
fig
short
incub
time
repres
worstcas
condit
fig
viru
inactiv
capac
plot
versu
incub
time
data
illustr
effect
viru
inactiv
achiev
rapidli
within
first
minut
sd
treatment
therefor
rapid
inactiv
envelop
virus
result
high
margin
safeti
product
scale
due
remain
time
still
avail
viru
inactiv
limit
detect
paramet
might
influenc
viru
inactiv
concentr
tnbp
found
critic
fig
reduc
concentr
tnbp
gl
correspond
standard
concentr
gl
reveal
signific
influenc
inactiv
test
virus
howev
tnbp
concentr
standard
concentr
result
delay
kinet
inactiv
expect
drastic
reduc
tnbp
concentr
lower
standard
concentr
fail
inactiv
test
virus
exampl
prv
andor
bvdv
limit
detect
lrf
valu
lower
log
studi
fig
howev
major
studi
effect
viru
inactiv
log
higher
demonstr
even
tnbp
concentr
lower
gl
robust
studi
significantli
reduc
concentr
tnbp
standard
concentr
limit
sd
treatment
becam
obviou
low
concentr
tnbp
critic
variabl
tnbp
essenti
combin
deterg
reduc
concentr
tnbp
also
impli
reduc
concentr
deterg
potenti
influenc
deterg
alon
decreas
concentr
deterg
standard
concentr
tnbp
address
studi
present
tnbp
almost
insolubl
aqueou
solut
thu
suffici
amount
deterg
essenti
effici
viru
inactiv
elev
concentr
tween
fviii
solut
gl
instead
gl
influenc
prv
inactiv
minut
treatment
mean
valu
inactiv
fig
time
point
minut
less
demonstr
rapid
kinet
viru
inactiv
within
first
minut
treatment
shown
mean
valu
inactiv
howev
rang
inactiv
larger
compris
even
valu
low
reduct
incub
time
minut
show
mean
lrf
valu
log
studi
inactiv
wnv
sarscov
reveal
emerg
envelop
virus
also
reliabl
inactiv
sd
treatment
confirm
valid
model
viru
concept
viru
valid
two
studi
perform
inactiv
vacv
previous
report
vacv
might
less
sensit
sd
treatment
special
structur
viru
particl
two
studi
present
vacv
effect
inactiv
combin
tnbptween
tnbpnachol
howev
two
studi
avail
data
limit
might
need
confirm
obviou
resist
test
virus
sd
treatment
observ
futur
robust
studi
bvdv
prv
may
recommend
prefer
test
virus
limit
inactiv
capac
could
demonstr
virus
robust
studi
low
tnbp
concentr
fig
emphas
studi
sd
treatment
perform
product
condit
residu
infect
treatment
observ
irrespect
class
product
combin
solvent
deterg
sd
concentr
gl
protein
concentr
gl
temperatur
rang
combin
tnbp
triton
even
lower
temperaturesand
ph
valu
reliabl
inactiv
envelop
virus
achiev
hour
incub
time
data
evalu
inactiv
log
minut
incub
time
studi
remain
process
variabl
minim
concentr
tnbp
deterg
list
tabl
data
might
limit
test
condit
test
strategi
differ
laboratori
indic
even
low
concentr
tnbp
deterg
gl
effect
inactiv
achiev
short
incub
time
base
studi
sd
treatment
conclud
ph
product
class
protein
concentr
even
low
incub
temperatur
signific
influenc
viru
inactiv
capac
drastic
reduc
concentr
tnbpdeterg
test
robust
studi
far
product
specif
identifi
critic
variabl
conclus
data
present
demonstr
robust
reliabl
efficaci
sd
treatment
establish
technolog
complet
inactiv
envelop
virus
hiv
wnv
hbv
hcv
sarscov
model
virus
sinv
bvdv
prv
eav
vsv
base
model
viru
concept
data
provid
assur
also
emerg
envelop
virus
exampl
sarscov
wnv
inactiv
sd
treatment
furthermor
data
emphas
effort
plasma
product
industri
whole
ensur
viral
safeti
product
consequ
today
document
transmiss
envelop
virus
hiv
hbv
hcv
envelop
virus
sdtreat
plasmaderiv
medicin
product
laboratori
data
present
confirm
long
clinic
experi
gener
manufactur
process
plasma
deriv
includ
sd
treatment
conjunct
effect
viru
inactivationremov
procedur
heat
treatment
viru
filtrat
orthogon
viral
safeti
measur
proven
highli
effect
reduc
elimin
risk
transmiss
envelop
virus
throughout
industri
